Arvind K. Sood | Amgen, Inc. |
Robert A. Bradway | Amgen, Inc. |
David W. Meline | Amgen, Inc. |
Anthony C. Hooper | Amgen, Inc. |
Sean E. Harper | Amgen, Inc. |
Christopher Raymond | Piper Jaffray |
Geoffrey C. Porges | Leerink Partners LLC |
Matthew K. Harrison | Morgan Stanley & Co. LLC |
Terence Flynn | Goldman Sachs & Co. LLC |
Robyn Karnauskas | Citigroup Global Markets, Inc. |
Ying Huang | Bank of America Merrill Lynch |
Eric Schmidt | Cowen and Co. LLC |
Umer Raffat | Evercore Group LLC |
Michael J. Yee | Jefferies LLC |
Geoffrey Meacham | Barclays Capital, Inc. |
Cory W. Kasimov | JPMorgan Securities LLC |
Alethia Young | Credit Suisse Securities (NYSE:USA) LLC |
Aharon Gal | Sanford C. Bernstein & Co. LLC |
Kennen Mackay | RBC Capital Markets LLC |
Andrew Peters | Deutsche Bank Securities, Inc. |
Salim Syed | Mizuho Securities USA, Inc. |
M. Ian Somaiya | BMO Capital Markets (United States) |
Jim Birchenough | Wells Fargo Securities LLC |
Carter Gould | UBS Securities LLC |
My name is Ian, and I will be your conference facilitator today for Amgen's Third Quarter 2017 Financial Results Conference Call. I would now like to introduce Arvind Sood, Vice President of Investor Relations. Mr.
Sood, you may now begin.
Okay.